Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates

(0 User reviews)   192   73
Alex Brown


Antibody-drug conjugates (ADCs) have revolutionized the field of targeted cancer therapy by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. ADCs have shown remarkable clinical success, leading to several FDA-approved therapies. However, the development of the next generation of ADCs presents new strategies and challenges that must be addressed to improve efficacy, safety, and therapeutic index. This article explores the innovative approaches taken to optimize ADC design, enhance tumor targeting, and overcome resistance mechanisms, while also discussing the challenges faced in the development of these promising therapeutics.

There are no reviews for this Publication.

0 out of 5 (0 User reviews )

Add a Review

Your Rating *
There are no comments for this Publication.
You must log in to post a comment.
Log in

Related Publications